Immutep Limited (IMMP)Healthcare | Biotechnology | Sydney, Australia | NasdaqGM
0.38 USD
+0.00
(0.053%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 0.39 +0.01 (2.362%) ⇧ (Aug. 28, 2026, 7:06 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:12 a.m. EDT
The investment case for Immutep is currently broken by a perfect storm of clinical failure and capital destruction. While the company boasts a fortress-like balance sheet with nearly $100 million in cash against negligible debt, the business fundamentals are deteriorating rapidly. The stock has lost over 80% of its value since the lung cancer trial halt, and the most recent annual data shows another significant drop, leaving the company with six negative years of performance versus only three positive ones in the last nine years. This is not a value opportunity; it is a distressed biotech play where the market has correctly priced out the risk of further failed trials. The lack of dividends and negative free cash flow confirms the company is burning through its war chest to fund R&D, with no guarantee of success. Although the cash pile provides a theoretical floor, the relentless downward pressure and the specific targeting of deep puts by traders suggest the market expects the remaining pipeline to face similar hurdles. Until a major clinical milestone reverses the trend, the risk-reward profile remains heavily skewed toward further losses. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.055379 |
| AutoARIMA | 0.056468 |
| AutoETS | 0.056470 |
| AutoTheta | 0.082399 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 0.44 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.250 |
| Excess Kurtosis | -1.09 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.223 |
| Revenue per Share | 0.05 |
| Market Cap | 56,148,784 |
| Forward P/E | -1.91 |
| Beta | 2.20 |
| Website | https://www.immutep.com |
As of Aug. 22, 2026, 5:12 a.m. EDT: Speculators are aggressively positioning for a crash, evidenced by massive open interest in deep out-of-the-money puts ($2.50 strikes) relative to calls. The implied volatility skew is extreme, with put IV significantly higher than call IV, indicating a market pricing in a high probability of further downside rather than a recovery.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.76829267 |
| Address1 | Australia Square |
| Address2 | Level 32 264 George Street |
| All Time High | 25.5 |
| All Time Low | 0.29 |
| Ask | 0.5023 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 91,830 |
| Average Daily Volume3 Month | 347,508 |
| Average Volume | 347,508 |
| Average Volume10Days | 91,830 |
| Beta | 2.195 |
| Bid | 0.287 |
| Bid Size | 2 |
| Book Value | 0.4793314 |
| City | Sydney |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Australia |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.381 |
| Current Ratio | 2.973 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 0.3915 |
| Day Low | 0.38 |
| Debt To Equity | 1.223 |
| Display Name | Immutep |
| Dividend Date | 1,482,883,200 |
| Earnings Timestamp End | 1,788,379,200 |
| Earnings Timestamp Start | 1,788,379,200 |
| Ebitda | -82,390,280 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.507 |
| Enterprise To Revenue | -5.272 |
| Enterprise Value | -41,771,112 |
| Eps Current Year | -0.32 |
| Eps Forward | -0.2 |
| Eps Trailing Twelve Months | -0.36 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 61 2 8569 1880 |
| Fifty Day Average | 0.3988 |
| Fifty Day Average Change | -0.017799973 |
| Fifty Day Average Change Percent | -0.044633836 |
| Fifty Two Week Change Percent | -76.82927 |
| Fifty Two Week High | 3.53 |
| Fifty Two Week High Change | -3.149 |
| Fifty Two Week High Change Percent | -0.89206797 |
| Fifty Two Week Low | 0.29 |
| Fifty Two Week Low Change | 0.09100002 |
| Fifty Two Week Low Change Percent | 0.31379318 |
| Fifty Two Week Range | 0.29 - 3.53 |
| Financial Currency | AUD |
| First Trade Date Milliseconds | 1,334,842,200,000 |
| Float Shares | 143,034,969 |
| Forward Eps | -0.2 |
| Forward P E | -1.9050001 |
| Free Cashflow | -35,678,096 |
| Full Exchange Name | NasdaqGM |
| Fullday Change | 0.000200003 |
| Fullday Change Percent | 0.0525219 |
| Fullday Price | 0.39 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -74,779,840 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.000120000004 |
| Held Percent Institutions | 0.01129 |
| Implied Shares Outstanding | 147,372,131 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.primabiomed.com.au/investor/ |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,751,241,600 |
| Last Split Date | 1,482,883,200 |
| Last Split Factor | 3:10 |
| Long Business Summary | Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia. |
| Long Name | Immutep Limited |
| Market | us_market |
| Market Cap | 56,148,784 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_6701589 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -83,916,456 |
| Next Fiscal Year End | 1,782,777,600 |
| Non Diluted Market Cap | 52,912,508 |
| Number Of Analyst Opinions | 1 |
| Open | 0.3846 |
| Operating Cashflow | -62,152,988 |
| Operating Margins | -7.63705 |
| Payout Ratio | 0.0 |
| Phone | 61 2 8315 7003 |
| Post Market Change | 0.008999974 |
| Post Market Change Percent | 2.3621976 |
| Post Market Price | 0.39 |
| Post Market Time | 1,787,958,371 |
| Previous Close | 0.3808 |
| Price Eps Current Year | -1.1906251 |
| Price Hint | 4 |
| Price To Book | 0.7948572 |
| Price To Sales Trailing12 Months | 7.087049 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.907 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.00020000339 |
| Regular Market Change Percent | 0.052521896 |
| Regular Market Day High | 0.3915 |
| Regular Market Day Low | 0.38 |
| Regular Market Day Range | 0.38 - 0.3915 |
| Regular Market Open | 0.3846 |
| Regular Market Previous Close | 0.3808 |
| Regular Market Price | 0.381 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 181,021 |
| Return On Assets | -0.32099 |
| Return On Equity | -0.61846 |
| Revenue Growth | 0.915 |
| Revenue Per Share | 0.05 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 147,372,131 |
| Shares Percent Shares Out | 0.0052 |
| Shares Short | 760,586 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 2,150,202 |
| Short Name | Immutep Limited |
| Short Percent Of Float | 0.0053 |
| Short Ratio | 3.96 |
| Source Interval | 15 |
| State | NSW |
| Symbol | IMMP |
| Target High Price | 1.5 |
| Target Low Price | 1.5 |
| Target Mean Price | 1.5 |
| Target Median Price | 1.5 |
| Total Cash | 99,129,496 |
| Total Cash Per Share | 0.673 |
| Total Debt | 1,209,606 |
| Total Revenue | 7,922,731 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.36 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.3273 |
| Two Hundred Day Average Change | -0.9462999 |
| Two Hundred Day Average Change Percent | -0.71295106 |
| Type Disp | Equity |
| Volume | 181,021 |
| Website | https://www.immutep.com |
| Zip | 2,000 |